计算溶液所需的质量、体积或浓度。
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.
In Vitro
Concentrations of Sapacitabine required to achieve an IC 50 range from 3±0.6 μM for the colon cancer cell line HCT116 to 67±14 μM for the breast cancer cell line MDA-MB-435. Cell cycle analysis shows that 35% Sapacitabine-treated cells are arrested in late-S phase and 41% in G 2 /M phase. L1210 cells with deoxycytidine kinase (dCK) activity are sensitive to Sapacitabine, (IC 50 20±6 μM). In the docetaxel/Sapacitabine combinations, synergistic effects (CI<1) are observed when docetaxel is given before Sapacitabine in both cell lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
On Day 14, the Sapacitabine (5 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 245 mm 3 and a tumour growth inhibition (TGI) of 92%, whereas the Sapacitabine (15 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 107 mm 3 and a TGI of 112%. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal administration
Female (nu/nu) mice are injected subcutaneously with 1×10 7 MV4-11 cells resuspended in 50% Matrigel at a single site on their flanks. Once tumour volumes are 126 to 256 mm 3 (16 days post-implantation) animals are pair matched by tumour size into treatment groups (minimum of six mice per group) with a mean tumour size of ~190 mm 3 . Tumour measurements are calculated using the formula: volume (mm 3 )=width 2 (mm)×length (mm)×0.5. Sapacitabine is administered once a day orally (5 or 15 mg/kg) for 4 days , followed by a 3-day break before another 4 days of treatment; dosing starts on the same day as distribution to the treatment groups . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:nucleoside analog
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 核苷、核苷酸及其类似物 |
| 类(Class) | 嘧啶核苷 |
| 亚类(Subclass) | 嘧啶2'-脱氧核糖核苷 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 嘧啶2'-脱氧核糖核苷 |
| 其他上位类(Alternative Parents) | N-芳基酰胺 嘧啶酮类 脂肪酰胺 咪唑内酰胺类 氢化嘧啶 四氢呋喃 杂芳族化合物 仲羧酸酰胺 仲醇 氮杂环化合物 氧环化合物 腈类 碳氢化合物衍生物 有机氧化物 有机光子化合物 羰基化合物 伯醇 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 羟基苯甲酸酯 - 芳香族杂单环化合物 - 氮杂环 - 碳腈 - 羰基 - 羧酰胺基 - 羧酸衍生物 - 脂肪酰基 - 脂肪酰胺 - 杂芳香族化合物 - 烃衍生物 - 羟吡啶 - 咪唑内酰胺 - N-芳基酰胺 - 氰基化合物 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 氧杂环 - 初级醇 - 嘧啶 - 嘧啶-2'-脱氧核糖核苷 - 嘧啶酮 - 醛基 - 醛基 - 四氢呋喃 |
| 描述(Description) | 该化合物属于嘧啶2'-脱氧核糖核苷类有机化合物。这类化合物由嘧啶与核糖连接而成,其核糖分子2位缺乏羟基。 |
| 外部描述符(External Descriptors) | 暂无 |
| ALogP | 5.2 |
|---|